SAT0212 Sarilumab dose reduction in an open-label extension study in ra patients with inadequate response to tnf inhibitors

Abstract

BackgroundSarilumab is a human mAb blocking the IL-6Rα. In the phase 3 TARGET study (NCT01709578), sarilumab (150 or 200 mg SC q2w) + csDMARDs demonstrated efficacy in adults with active,...